CMND - What's Going On With Clearmind Medicine Stock Tuesday? | Benzinga
Clearmind Medicine Inc (NASDAQ:CMND) on Tuesday announced advancement in its proprietary MEAI-based alcohol substitute beverage program.
What Happened: Clearmind previously announced the initiation of the last pre-clinical study required for a novel-food application submission. The project is being led by former Red Bull Canada and Juul Labs Canada executive Nicholas Kadysh, who is serving as a special advisor to the company.
On Tuesday, Clearmind said its alcohol substitute was granted patents in the U.S., India and Europe. The company also highlighted that the no/low alcohol category is forecasted to grow at a volume CAGR of more than 6% between 2023 and 2027.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery ...